AD_____

Award Number: DAMD17-01-1-0557

TITLE: The Role of Stat3 in Breast Cancer Tumorigenesis

PRINCIPAL INVESTIGATOR: Jacqueline F. Bromberg, M.D., Ph.D.

CONTRACTING ORGANIZATION: Sloan-Kettering Institute for Cancer Research New York, New York 10021

REPORT DATE: September 2002

TYPE OF REPORT: Final

- PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012
- DISTRIBUTION STATEMENT: Approved for Public Release; Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20030128 133

Charlencome Construction Construction </th <th colspan="3">REPORT DOCUMENTATION PAGE</th> <th>c</th> <th colspan="2">Form Approved</th>	REPORT DOCUMENTATION PAGE			c	Form Approved		
Discrete investige investige and senses in the sense of the sense in the	Public reporting burden for this collection of inform	nation is estimated to average 1 hour per response, ais collection of information. Send comments regar	including the time for reviewing in ding this burden estimate or any o	structions, searching e	xisting data sources, gathering and maintaining ection of information, including suggestions for		
1. AGENCY USE ONLY (Leave blank) 2. REPORT DATE S. REPORT TYPE AND DATES COVERED 4. TITLE AND SUBTILE Final (20 Aug 01 - 13 Aug 02) 4. TITLE AND SUBTILE Final (20 Aug 01 - 13 Aug 02) 4. TITLE AND SUBTILE Final (20 Aug 01 - 13 Aug 02) 6. AUTHOR(S): Jaccobing of the second of th	reducing this burden to Washington Headquarter Management and Budget, Paperwork Reduction I	s Services, Directorate for Information Operations a Project (0704-0188), Washington, DC 20503	and Reports, 1215 Jefferson Davis	Highway, Suite 1204,	Arlington, VA 22202-4302, and to the Office of		
4. TITLE AND SUBTILE 1. SEPTIMENT 2002 FINAL (20 Aud 01 - 15 Aud 02) 5. FUNDAMEN NUMBERS 5. FUNDAMEN NUMBERS DADD17-01-1-0557 5. FUNDAMEN NUMBERS Jacqueline F. Bromberg, M.D., Ph.D. 5. FUNDAMEN NUMBERS 7. FEBFORMING ORGANIZATION NAME(SI AND ADDRESS(ES) 5. FUNDAMEN ORGANIZATION NAME(SI AND ADDRESS(ES) Sloan-Rettering Institute for Cancer Research 8. PERFORMING ORGANIZATION New York, New York 10021 10. SPONSORING / MONITORING AGENCY NAME(SI AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command 10. SPONSORING / MONITORING AGENCY NAME(SI AND ADDRESS(ES) 11. SUPPLEMENTARY NOTES 10. SPONSORING / MONITORING AGENCY NAME(SI AND ADDRESS(ES) 12a. DISTRIBUTION / AVAILABILITY STATEMENT 12b. DISTRIBUTION CODE 11. SUPPLEMENTARY NOTES 12b. DISTRIBUTION CODE 12a. DISTRIBUTION / AVAILABILITY STATEMENT 12b. DISTRIBUTION code and cancer derived cell lines, where growth factor dyscegulation is often at the heart of transformation, enhances transformation, sonstutively during adviated Stata sonstutively and transformation consultatively attivated. In a number of cancer derived cell lines, constitutively attivated. In a number of cancer derived cell lines of transformation of phospho-Stata sonstutively attivated. In a number of cancer derived cell lines are processed the number of ancer derived cell lines to phospho-Stata sonstutively attivated. In a number of acacer derived cell lines constitutively attivated. In a number of acancer d	1. AGENCY USE ONLY (Leave blan	k) 2. REPORT DATE	3. REPORT TYPE AND	DATES COVER	ED		
11. SUPPLEMENTARY NOTES 12. DISTRIBUTION / AVAILABLITY STATEMENT Approved for Public Release; Distribution Unlimited 13. Abstract (Maximum 200 Works) (abstract should contain no proceeding with a sport of monotalized breast cancer samples and cancer stansformation, enhances transformation, subserved in that unless to priorese. The approved for Public Release; Distribution Unlimited 13. Abstract (Maximum 200 Works) (abstract should contain no proceeding with a sport of monotalized breast provide stand and under standing and mumor of cancer derived cell lines, where growth factor dyregulation is often at the heart of transformation, standing as a proto-monogene. The purpose of the constitutively activated Stat) is either required for transformation, enhances transformation, processed with 30 minutes of removal from the unless the priores of the constitutively activated Stat) is either required for transformation, enhances transformation, processed with 30 minutes of tensor of phospho-Stat) discrimed Musteriel Common Statischemical evel of the constitutively activated Statis as a proto-monogene. The purpose of the Concept Proposal (DAMDI 7-01-1-10-55) and the statischemical and immunohistochemical techniques the abundance and distribution 0 minutes of tensor of the processed (MAMDI 70-01-1-01-01-01-01-01-01-01-01-01-01-01-		September 2002	Final (20 Aug	01 - 19 Au	Ig U2)		
6. AUTHONIS: Jacqueline F. Bromberg, M.D., Ph.D. 7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Sloan-Kettering Institute for Cancer Research New York, New York 10021 E.Mail: bromberj@mskcc.org 9. SPONSORMC / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSORMC / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 11. SUPPLEMENTARY NOTES 12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. Abstract (Maximum 200 Words) (abstract should contain no proprietary or confidential information) In a growing number of cancers and Cancer derived cell lines, where growth factor dysregulation is often at the heart of transformation, enhancer stransformation or blocks apoptosis. Introduction of clifer anti-sense or dominant required for transformation, enhancer stransformation or blocks apoptosis. Introduction of clifer anti-sense or dominant required for transformation, enhancer stransformation or blocks apoptosis. Introduction of clifer anti-sense or dominant required for transformation, enhancer stransformation or blocks apoptosis. Introduction of clifer anti-sense or dominant required by both biochemical and immundhistochemical techniques the abudance and distribution of phospho-Stat3 decreased substatially. Analysis of archival partitin tisse sections gave the most reproducible results and revealed that - 35% of primary breast cancer samples contained high levels of phospho-Stat3. A positive correlation with B-C2 and the sections gave the most reproducible results and revealed that - 35% of primary breast cancer samples contained high levels of phospho-Stat3. A positive correlation with B-C2 and Seng	The Role of Stat3	in Breast Cancer Tu	morigenesis	DAMD17-01-1-0557			
6. AUTHORIS:: Jacqueline F. Bromberg, M.D., Ph.D. 7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Sloan-Kettering Institute for Cancer Research New York, New York 10021 E-Mail: bromberj@mskc2.org 8. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 11. SUPPLEMENTARY NOTES 12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. Abstract (Maximum 200 Words) (abstract should contain no proprietary or confidential information) In a growing number of cancer and cancer derived cell lines, where growth factor dysregulation is often at the heart of transformation, Sta3 (one of the STAT proteins) is constitutively activated. In a number of cancer derived cell lines, where growth factor dysregulation is often at the heart of transformation, Sta3 (one of the STAT proteins) is constitutively activated. In a number of cancer derived cell lines, where growth factor dysregulation is often at the heart of transformation, Sta3 (one of the STAT proteins) is constitutively activated. In a number of cancer derived cell lines including breast cancer leads to their apports. We have engineered a constitutively dimensional termidy static is capability in throatise of transformation of inducing cell transformation of Simbolity Simbolity in gativated Sta3 signal. However, tissue arrays gave the most reproducible results and revealed from the patient, that he levels of phospho-Sta3 signal. However, tissue arrays gave the most reproducible results and revealed from the strength of the phospho-Sta3 signal. However, tissue arrays gave the most reproducible results and revealed frat - 35% of primary breast cancer			5				
6. AUTORIS: Jacqueline F. Bromberg, M.D., Ph.D. 7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Sloan-Kettering Institute for Cancer Research New York, New York 10021 E.Mai: bromberj@mskcc.org 9. SFONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Material Command Fort Detrick, Maryland 21702-5012 11. SUPPLEMENTARY NOTES 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. Abstract (Meximum 200 Works) (Additat should contain no proceedary or confidential Informatica) In a growing number of cancers and cancer derived cell lines, where growth factor dyargulation is often at the heart of transformation, Sta3 (one of the STAT proteins) is constitutively activated. In a number of cancer derived cell lines including breast cancer derived cell lines, constitutively activated Sta15 is in a number of cancer derived cell lines, where growth factor dyargulation is often at the heart of transformation, Sta3 (one of the STAT proteins) is constitutively activated. In a number of cancer derived cell lines including breast cancer candidated informatica) 10. Sponsoal (DAMD)7-01-1- 0557) was to 1) Identify by both biochemical and immundivischemical techniques the abundance and distribution of phospho-Sta33 form the patient, that the levels of phospho-Sta33 decreased substantially. Analysis of archival parafin tisses setting services and sciences approxis. No have regulated cancer samples contained have samples expressing strong. Pista3. A positive correlation with R2 and PK but an inverse correlation with BC and PK but an immundhistochemicalty, India parafin tisses setting setting state, PIAS3 mRNA in matched normal versus tumour samples and determined (to our surgiss) that PIAS3 levels were higher that the active carcinogeneesis, immunchistochemistry, breast cancer 15. NUMBER OF PAGES 17. SECURITY CLASSIFICATION 18. SECURITY CLASSIFICATION 19. SECURITY CLASSIFICATION 19. SECURITY CLASSIFICATION 19. SECURITY CLASSIFICAT							
Jacqueline F. Bromberg, M.D., Ph.D. 7. PERFORMING ORGANIZATION NAME(5) AND ADDRESS(E5) Sloan-Kettering Institute for Cancer Research New York, New York 10021 E.Mai: bromber@mskcc.org 9. sPONSORING / MONITORING AGENCY NAME(5) AND ADDRESS(E5) 10. SPONSORING / MONITORING AGENCY NAME(5) AND ADDRESS(E5) 11. SUPPLEMENTARY NOTES 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. Abstract (Maximum 200 Words) (Abstract should contain no processing or work for an under of lines including breast cancer derived cell lines, constitutively dimerizable Stat3, termed Stat3 or a processed "within 30 inducts of removal for montalized breast cancer derived cell lines, where growth factor dysregulation is often at the heart of transformation of blocks approxiss. Introduction of either anti-sense or dominant negative Stat3 in a number of cancer derived cell lines including breast cancer derived cell lines including breast cancer leads to their approxiss. We have engineered a constitutively distribution (blocks approxiss). Introduction of either anti-sense or dominant negative Stat3 in a number of cancer derived cell lines including breast cancer leads to their approxis. We have engineered a constitutively distribution dominant including stat cancer and distribution of phospho-Stat3 in primary breast cancer samples. We determined that unless the primary sample was "processed" within 30 innutes of phospho-Stat3 signal. However, tissue arrays gave the most reproduction with Rev and phospho-Stat3 signal. However, tissue arrays gave the most reproduction with Rev and Phospho-Stat3 signal. However, tissue arrays gave the most reproduction with Rev and Phospho-Stat3 signal. However, tissue arrays gave the most reproduction with Rev and Phospho-Stat3 signal. However, tissue arrays gave the most reproduction with Rev and Phospho-Stat3 signal. However, tissue arrays gave the most reproduction with Rev and Phospho-Stat3 signal. However, tissue arrays gave the most reproduction with Rev R	6. AUTHOR(S):			1			
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) 8. PERFORMING ORGANIZATION Sloan-Kettering Institute for Cancer Research REPORT NUMBER Sloan-Kettering Institute for Cancer Research REPORT NUMBER E-Mai: bromberj@mskcc.org 10. sponsoring / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. sponsoring / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army McGical Research and Materiel Command Addressearch and Materiel Command AGENCY REPORT NUMBER 11. SUPPLEMENTARY NOTES 12. DISTRIBUTION / AVAILABILITY STATEMENT Agency report NUMBER 13. Abstract (Machnum 200 Words) (abstract should contain no proprietary or confidentia Information) In a growing number of cancers and cancer derived cell lines, where growth factor dysregulation is often at the heart of transformation, Stat3 (one of the STAT proteins) is constitutively activated. In a number of cancer derived cell lines, including sequence derived cell lines, sconstitutively activated Stat3 is either required for transformation, enhances transformation or blocks apoptosis. Introduction of either anti-sensee or dominant negatives Stat3 in a number of cancer derived cell lines including beet including cell transformation of finomoralized breast epithetial cells, thus qualifying activated Stat3 as a proto-oncogene. The purpose of the Concept Proposal (DAMD17-01-1-10-1) Syn vs to 1) Identify by both biochemical and immunohistochemical techniques the abundance and distribution of phospho-Stat3 in primary breast energy and phospho-Stat3 decreased substatially. Analysis of archival parafin fisues sectored with abisue acreasangles contained in the Ness of the Stat3 ne	Jacqueline F. Brom	berg, M.D., Ph.D.					
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) 8. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Sloan-Kettering Institute for Cancer Research REPORT NUMBER New York, New York 10021 10. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) J. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 10. SPONSORING / MONITORING AGENCY REPORT NUMBER 11. SUPPLEMENTARY NOTES 12b. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 12b. DISTRIBUTION CODE 13. Abstract (Maximum 200 Words) (abstract should contain no proprietary or confidential information) 11 na agrowing number of cancers and cancer derived cell lines; where growth factor dysregulation is often at the heart of transformation, STAT (one of the STAT proteins) is constitutively activated. In a number of cancer derived cell lines; including breast cancer derived cell lines, constitutively activated is no number of cancers and scive det Stat3 is often required for transformation, enhances transformation or blocks apoptosis. Introduction of either anti-sense or dominant negative Stat3 in a number of cancer derived cell lines including breast cancer leads to their apoptosis. We have engineered a constitutively dimerizable Stat3, termed Stat3-C, which is capable of inducing copies (DAMD)-10-1-10- S57) vas to 1) Identify by both biochemical and immunohistostatility. Analysis of archival paraffin tissue sections gave mixed results regarding the strength of the phospho-Stat3 discresads subatstintily. Analysis of archival paraffin tissu							
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) 8. PERFORMING ORGANIZATION Sloan-Kettering Institute for Cancer Research New York, New York 10021 New York, New York 10021 10. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command 10. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command 10. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 11. SUPPLEMENTARY NOTES 10. SPONSORING / MONITORING CADERSS(ES) 12. DISTRIBUTION / AVAILABILITY STATEMENT Agency REPORT NUMBER Approved for Public Release; Distribution Unlimited 12b. DISTRIBUTION CODE 13. Abstract (Maximum 200 Words) (abstract should contain no proprietary or confidential information) 11a growing number of cancers and cancer derived cell lines; here growth factor dysregulation is often at the heart of transformation, stati (one of the STAT proteins is constitutively scituated. In a number of cancer derived cell lines; here dimensitively dimerizeable Stat3, termed Stat3-C, which is capable of inducing cell transformation of inmortalized stata so their apptosis. We have engineered a constitutively dimerizeable Stat3, termed Stat3-C, which is capable of inducing cell transformation of phospho-Stat3 in primary breast cancer samples way forco-ncocgene. The purpose of the Concept Proposal (DAMD1/-01-1-0557) was to 1) dentify by both biochemical and immunohistochemical techniques the abundance and distribution of phospho-Stat3 decreased substantially. Analysis of archival paraffin tissue sections gave mixed results and revealed that							
Sloan-Kettering Institute for Cancer Research New York, New York 10021 In Som Komick E-Mail: bromberj@(mskcc.org) In Sponsoning / MONITORING AGENCY NAME(S) AND ADDRESS(ES) In Sponsoning / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 In Sponsoning / MONITORING AGENCY REPORT NUMBER 11. SUPPLEMENTARY NOTES In Sponsoning / MONITORING AGENCY REPORT NUMBER 12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 12b. DISTRIBUTION CODE 13. Abstract (Maximum 200 Words) (abstract should contain no proprietary or confidential information) In a growing number of cancers and cancer derived cell lines, where growth factor dysregulation is often at the heart of transformation, Stat3 (one of the STAT proteins) is constitutively activated. In a number of cancer derived cell lines, onstitutively activated. Stat3 is cither required for transformation, enhances transformation or blocks apoptosis. Introduction of either anti-sense or dominant negative Stat3 in a number of cancer derived cell lines, including breast cancer leads to their apoptosis. We have engineered a constitutively dimerizeable Stat3. termed Stat3-C, which is capable of inducing cell transformation of himospho-Stat3 in primary breast cancer samples. We determined that unless the primary sample was "processed" within 30 minutes of removal from the patient, that the levels of phospho-Stat3 derive results agarding the strength or the patient, that the levels of phospho-Stat3 derive regulator, PLAS3 levels were higher in the tumors containing phospho-Stat3. We generated MMTV Stat3-C cince in collaboration with RCan dPR but an inverse correlation with her2neu was obse	7. PERFORMING ORGANIZATION N	IAME(S) AND ADDRESS(ES)		8. PERFORMING ORGANIZATION REPORT NUMBER			
New York, New York 10021 E.Mai: bromberj@mskoc.org g. sponsoning / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 11. SUPPLEMENTARY NOTES 12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. Abstract (Maximum 200 Words) (abstract should contain no accontentry or confidential information) 1a growing number of cancers and cancer derived cell lines, where growth factor dysregulation is often at the heart of transformation, Stat3 (one of the STAT proteins) is constitutively activated. In a number of cancer service call files, constitutively activated Stat3 is a number of cancer derived cell lines, including breast cancer leads to their approximation or blocks apoptosis. Introduction of immortalized engineered a constitutively dimerizeable Stat3, termed Stat3-C, which is capable of inducing cell tarsformation of finantoralized from the patient, that the levels of phospho-Stat3 dimerized stat3 signal. However, tissue arrays gave the most reproducible results and revealed dim the patient, that the levels of phospho-Stat3 signal. However, tissue arrays gave the most reproducible results and revealed dim the patient, that the levels of phospho-Stat3 signal. However, tissue arrays gave the most reproducible results and revealed dim the state scencer samples scontained dim levels of phospho-Stat3 signal. However, tissue arrays gave the most reproducible results and revealed dim the state check array samples and determined (to consel surges) that PASS levels were higher in the tumors containing phospho-Stat3. We generated MMTY Stat3-C mice in collaboration with Robert Schriber. Unfortunately, Stat3-C expression is exceedingly low and the	Sloan-Kettering Instit	ute for Cancer Research	ı				
E. Mail: bromberj@mskcc.org 9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 11. SUPPLEMENTARY NOTES 12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. Abstract (Maximum 200 Words) (abstract should contain no proprietary or confidential informatica) In a growing number of cancers and cancer derived cell lines, where growth factor dysregulation is often at the heart of transformation, Stat3 (one of the STAT proteins) is constitutively activated. In a number of cancer derived cell lines, constitutively activated Stat3 is either required for transformation, enhances transformation or blocks apoptosis. Introduction of either anti-sense or dominant negative Stat3 in a number of cancer derived cell lines including breast cancer leads to their apoptosis. We have engineered a constitutively dimerizable Stat3, termed Stat3C, which is capable of inducing cell transformation of hinorchaized breast epithelial cells, thus qualifying activated Stat3 as a proto-oncogene. The purpose of the Concept Proposal (DAMD17-01-1-0557) was to 1) Identify by both biochemical and immunohistochemical techniques the abundance and distribution of phospho-Stat3 in primary breast cancer samples. We determined that unless the primary sample was "processed" within 30 minutes of removal from the patient, that the levels of phospho-Stat3 excreased substatially. Analysis of archival parafin tissue sections gave mixed results regarding the strength of the phospho-Stat3 secressed substatially. Analysis of archival parafin tissue sections gave mixed revelded that ~ 35% of primary breast cancer samples contained high	New York, New York 10	021					
E-Mail: bromberj@mskcc.org 10. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 11. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Adency Report NUMBER Fort Detrick, Maryland 21702-5012 11. SUPPLEMENTARY NOTES 11. SUPPLEMENTARY NOTES 12b. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 12b. DISTRIBUTION CODE 13. Abstract (Maximum 200 Words) (abstract should contain no proprietary or confidential information) 11 In a growing number of cancers and cancer derived cell lines, where growth factor dysregulation is often at the heart of transformation, enhances transformation or blocks apoptosis. Introduction of either anti-sense or dominant negative Stati is either required for transformation, enhances transformation or blocks apoptosis. Introduction of either anti-sense engineered a constitutively dimerizeable Stat3, termed Stat3-C, which is capable of inducing cell transformation of Immortalized breast epithelial cells, thus qualifying activated Stat3 as a proto-oncogene. The purpose of the Concept Proposal (DAMD) 7-01-1-057) was to 1 (DAMD) 7-01-1-0530 decreased substatially. Analysis of archival paraffin tissue sections gave mixed results regarding the strength of the phospho-Stat3 as a proto-oncegene. The purpose of the Concept Proposal (DAMD) 7-01-1-0057) was to 1 (DAMD) 7-01-1-0057) was to 3 protopho-Stat3. A positive correlation with EA and PR but an inverse correlation with becase of phospho-Stat3 decreased substatially. Nanalysis of archival paraffin tissue sections gave mixed results and revealed that -35% of primary breast cancer samples. Contained high levels of phosph							
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Security Comments Fort Detrick, Maryland 21702-5012 11. SUPPLEMENTARY NOTES 11. SUPPLEMENTARY NOTES 12b. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 12b. DISTRIBUTION CODE 13. Abstract (Maximum 200 Words) (abstract should contain no proprietary or confidential information) 11a In a growing number of cancers and cancer derived cell lines, where growth factor dysregulation is often at the heart of transformation, enhances transformation or blocks apoptosis. Introduction of either anti-sense or dominant negative Sta3 is either required for transformation, enhances transformation or blocks apoptosis. Introduction of either anti-sense or dominant negative Sta3 is either adultifying activated Sta13.cc, which is capable of inducing cell transformation of mimortalized breast epithelial cells, thus qualifying activated Sta13 expression (AMDI 7-01-1-10057) was to 1) Identify by both biochemical and immunohistochemical techniques the abundance and distribution of phospho-Sta13 in primary breast cancer samples. We determined that unless the primary sample was "processed" within 30 minutes of removal from the patient, that the levels of phospho-Sta13 decreased substantially. Analysis of archival paraffin tissue sections gave mixed regulator, PIAS3 mRNA in matched normal versus tumour samples and determined (to our surprise) that PIAS3 levels were higher in the tumors ontaining phospho-Sta13. We generated MMTV Sta13-C mice in collaboration with Robert Schriber. Unfortunately, Sta1-C expression is ex	E-Mail: bromberj@mskcc.org						
AGENCY REPORT NUMBER AGENCY REPORT NUMBER AGENCY REPORT NUMBER AGENCY REPORT NUMBER Fort Detrick, Maryland 21702-5012 AGENCY REPORT NUMBER Fort Detrick, Maryland 21702-5012 T1. SUPPLEMENTARY NOTES T2a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited T3. Abstract (Maximum 200 Words) (abstract should contain no proprietary or confidential information) In a growing number of cancers and cancer derived cell lines, where growth factor dysregulation is often at the heart of transformation, Stat3 (one of the STAT proteins) is constitutively activated. In a number of cancer derived cell lines, constitutively activated Stat3 is either required for transformation, enhances transformation or blocks apoptosis. Introduction of either anti-sense or dominant negative Stat3 in a number of cancer derived cell lines including breast cancer leads to their apoptosis. We have engineered a constitutively dimerizeable Stat3, termed Stat3-C, which is capable of inducing cell transformation of fimmortalized breast epithelial cells, thus qualifying activated Stat3 as proto-oncogene. The purpose of the Concept Proposal (DAMD17-01-1- 0557) was to 1) Identify by both biochemical and immunohistochemical techniques the abundance and distribution of phospho-Stat3 in primary breast cancer samples. We determined that unless the primary sample was "processed" within 30 minutes of removal from the paties tancer samples. We determined hall heles of phospho-Stat3 is and revealed that ~ 35% of primary breast cancer samples contained high levels of phospho-Stat3. A positive correlation with RF and PR but an inverse correlation with her2neu was observed in those samples ary groups from containing phospho-Stat3 levels were higher in the tumors containing phospho-Stat4. A positive correlation with RF and PR but an inverse containing phospho-Stat4. We generated HMITY Stat3-C mice in collaboration with RA PA BV and apative regulator, PIAS3 mRNA in matched normal versus tumour samples and determined (to our surpris	9. SPONSORING / MONITORING A	GENCY NAME(S) AND ADDRESS(E	5)	10. SPONSOR	ING / MONITORING		
U.S. Army Medical Research and Material Command Fort Detrick, Maryland 21702-5012 11. SUPPLEMENTARY NOTES 12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. Abstract (Maximum 200 Words) (abstract should contain no proprietary or confidential information) In a growing number of cancers and cancer derived cell lines, where growth factor dysregulation is often at the heart of transformation, Stat3 (one of the STAT proteins) is constitutively activated. In a number of cancer derived cell lines, constitutively activated Stat3 is either required for transformation, enhances transformation or blocks apoptosis. Introduction of either anti-sense or dominant negative Stat3 in a number of cancer derived cell lines including breast cancer leads to their apoptosis. We have engineered a constitutively dimerizeable Stat3, termed Stat3-C, which is capable of inducing cell transformation of blocks apoptosis. Introduction of either anti-sense or dominant negative Stat3 as a proto-oncogene. The purpose of the Concept Proposal (DAMD17-01-1-0557) was to 1) Identify by both biochemical and immunohistochemical techniques the abundance and distribution of phospho-Stat3 formed Stat3 signal. However, tissue arrays gave the most reproducible results are revealed that ~ 35% of primary breast cancer samples. We determined that unless the primary sample was "processed" within 30 minutes of the subta and inverse correlation with herZneu was observed in those samples expressing strong p-Stat3. A positive correlation with ER and PR but an inverse tormoral revealed thing levels of phospho-Stat3. A positive correlation with ER and PR but an inverse containing phospho-Stat3. We generated MMTV Stat3-C mice in collaboration with RDAS3 levels were higher in the tumors con				AGENCY	REPORT NUMBER		
11. SUPPLEMENTARY NOTES 12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 12b. DISTRIBUTION CODE 13. Abstract (Maximum 200 Words) (abstract should contain no proprietary or confidential information) 11n a growing number of cancers and cancer derived cell lines, where growth factor dysregulation is often at the heart of transformation, Stat3 (one of the STAT proteins) is constitutively activated. In a number of cancer derived cell lines, sconstitutively activated Stat3 is either required for transformation, enhances transformation or blocks apoptosis. Introduction of either anti-sense or dominant negative Stat3 in a number of cancer derived cell lines including breast cancer leads to their apoptosis. We have engineered a constitutively dimerizeable Stat3, termed Stat3-C, which is capable of inducing cell transformation or biospho-Stat3 in primary breast cancer samples. We determined that unless the primary sample was "processed" within 30 minutes of removal from the patient, that the levels of phospho-Stat3 decreased substantially. Analysis of archival paraffin tissue sections gave mixed results regarding the strength of the phospho-Stat3 decreased substantially. Analysis of archival paraffin tissue sections gave mixed from the patient, that the levels of phospho-Stat3 decreased substantially. Analysis of archival paraffin tissue sections gave mixed results regarding the strength of the phospho-Stat3 decreased substantially. Analysis of archival paraffin tissue sections gave mixed from the patient, Phospho-Stat3. We generated MMTV Stat3-C mice in collaboration with Rest and Pk but an inverse correlation with her and Pk but an inverse correlation with her and PK but an inverse correlation with Rest and Pk but an	U.S. Army Medical Research and Fort Detrick Maryland 21702-5	012					
11. SUPPLEMENTARY NOTES 12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 12b. DISTRIBUTION CODE 13. Abstract (Maximum 200 Words) (abstract should contain no proprietary or confidential information) 1a 1a growing number of cancers and cancer derived cell lines, where growth factor dysregulation is often at the heart of transformation, Stat3 (one of the STAT proteins) is constitutively activated. In a number of cancer derived cell lines, where engineered a constitutively dimerizeable Stat3, termed Stat3-C, which is capable of inducing cell transformation of inmortalized breast epithelial cells, thus qualifying activated Stat3 as a proto-oncogene. The purpose of the Concept Proposal (DAMDI 7-01-1- 0577) was to 1) Identify by bot biochemical and immunohistochemical techniques the abundance and distribution of phospho-Stat3 in primary breast cancer samples. We determined that unless the primary sample was "processed" within 30 minutes of removal from the patient, that the levels of phospho-Stat3 decreased substantially. Analysis of archival paraffin tissue sections gave mixed from the patient, that the levels of phospho-Stat3 decreased substantially. Analysis of archival paraffin tissue sections gave mixed from the patient, that the levels of phospho-Stat3 decreased substantially. Analysis of archival paraffin tissue are veled that ~ 35% of primary breast cancer samples contained high levels of phospho-Stat3. A positive correlation with RET and PR but an inverse correlation with her2neu was observed in those samples expressing strong p-Stat3. We examined levels of the Stat3 negative regulator, PLAS3 mRNA in matched normal versus tumour samples and determined (to our surprise) that PLAS3 Levels were higher in the tumors containing phospho-Stat3. We generated MMTV Stat3-C mice in collaboration with Robert Schribe	Fort Detries, Waryland 21702-5	012					
11. SUPPLEMENTARY NOTES 12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 12b. DISTRIBUTION CODE 13. Abstract (Maximum 200 Words) (abstract should contain no proprietary or confidential information) 11 In a growing number of cancers and cancer derived cell lines, where growth factor dyregulation is often at the heart of transformation, Stat3 (one of the STAT proteins) is constitutively activated. In a number of cancer derived cell lines, constitutively activated Stat3 is either required for transformation, enhances transformation or blocks apoptosis. Introduction of either anti-sense or dominant negative Stat3 in a number of cancer derived cell lines including breast cancer leads to their apoptosis. We have engineered a constitutively dimerizeable Stat3, termed Stat3-C, which is capable of inducing cell transformation of fimortalized breast epithelial cells, thus qualifying activated Stat3 as a proto-oncogene. The purpose of the Concept Proposal (DAMD17-01-1- 0557) was to 1) Identify by both biochemical and immunohistochemical techniques the abundance and distribution of phospho-Stat3 in primary breast cancer samples. We determined that unless the primary sample was "processed" within 30 minutes of removal from the patient, that the levels of phospho-Stat3 decreased substantially. Analysis of archival paraffin tissue sections gave mixed results regarding the strength of the phospho-Stat3 ginal. However, tissue arrays gave the most reproducible results and revealed that ~ 35% of primary breast cancer samples contained high levels of phospho-Stat3. A positive correlation with ER and PR but an inverse correlation with her2neu was observed in those samples axpressing strong p-Stat3. We examined levels of the Stat9 levels were higher in the tumors containing phospho-Stat3. We generated MMTV Stat3-C mice in colla							
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. Abstract (Maximum 200 Words) (abstract should contain no proprietary or confidential information) In a growing number of cancers and cancer derived cell lines, where growth factor dysregulation is often at the heart of transformation, Stat3 (one of the STAT proteins) is constitutively activated. In a number of cancer derived cell lines, constitutively activated Stat3 is either required for transformation, enhances transformation or blocks apoptosis. Introduction of either anti-sense or dominant negative Stat3 in a number of cancer derived cell lines including breast cancer leads to their apoptosis. We have engineered a constitutively dimerizeable Stat3, termed Stat3-C, which is capable of inducing cell transformation of immortalized breast epithelial cells, thus qualifying activated Stat3 as a proto-nocogene. The purpose of the Concept Proposal (DAMD17-01-1.0557) was to 1) Identify by both biochemical and immunohistochemical techniques the abundance and distribution of phospho-Stat3 in primary breast cancer samples. We determined that unless the primary sample was "processed" within 30 minutes of removal from the patient, that the levels of phospho-Stat3 signal. However, tissue arrays gave the most reproducible results and revealed that ~ 35% of primary breast cancer samples contained high levels of phospho-Stat3. A positive correlation with her2neu was observed in those samples expressing strong p-Stat3. We examined levels of the bospho-Stat3 signal. However, tissue arrays gave the most reproducible results and revealed that ~ 35% of primary breast cancer samples. We determined that unless of prospho-Stat3. A positive correlation with her2neu was observed in those samples expressing strong p-Stat3. We examined levels of the Stat3 negative regulator, PIAS3 mRNA in matched normal vers				1			
12a. DISTRIBUTION / AVAILABILITY STATEMENT 12b. DISTRIBUTION CODE Approved for Public Release; Distribution Unlimited 12b. DISTRIBUTION CODE 13. Abstract (Maximum 200 Words) (abstract should contain no proprietary or confidential information) 1 In a growing number of cancers and cancer derived cell lines, where growth factor dysregulation is often at the heart of transformation, Stat3 (one of the STAT proteins) is constitutively activated. In a number of cancer derived cell lines, constitutively activated Stat3 is either required for transformation, enhances transformation or blocks apoptosis. Introduction of either anti-sense or dominant negative Stat3 in a number of cancer derived Stat3 - C, which is capable of inducing cell transformation of immortalized breast epithelial cells, thus qualifying activated Stat3 as a proto-oncogene. The purpose of the Concept Proposal (DAMD17-01-1-0557) was to 1) Identify by both biochemical and immunohistochemical techniques the abundance and distribution of phospho-Stat3 in primary breast cancer samples. We determined that unless the primary sample was "processed" within 30 minutes of removal from the patient, that the levels of phospho-Stat3 decreased substantially. Analysis of archival paraffin tissue sections gave mixed results regarding the strength of the phospho-Stat3 signal. However, tissue arrays gave the most reproducible results and revealed that ~ 35% of primary breast cancer samples contained high levels of phospho-Stat3. A positive correlation with ER and PR but an inverse contelation with her2neu was observed in those samples and determined (to our surprise) that PIAS3 levels were higher in the tumors containing phospho-Stat3. We generated MMTV Stat3-C mice in collaboration with Robert Schriber. Unfortunately, Stat3-C expression is exceedingly low and the animals do not have any unusual	11. SUPPLEMENTARY NOTES						
12a. DISTRIBUTION / AVAILABILITY STATEMENT 12b. DISTRIBUTION CODE Approved for Public Release; Distribution Unlimited 12b. DISTRIBUTION CODE 13. Abstract (Maximum 200 Words) (abstract should contain no proprietary or confidential information) In a growing number of cancers and cancer derived cell lines, where growth factor dysregulation is often at the heart of transformation, Stat3 (one of the STAT proteins) is constitutively activated. In a number of cancer derived cell lines, constitutively activated Stat3 is either required for transformation, enhances transformation or blocks apoptosis. Introduction of either anti-sense or dominant negative Stat3 in a number of cancer derived cell lines including breast cancer leads to their apoptosis. We have engineered a constitutively dimerizeable Stat3, termed Stat3-C, which is capable of inducing cell transformation of immortalized breast epithelial cells, thus qualifying activated Stat3 as a proto-oncogene. The purpose of the Concept Proposal (DAMD17-01-1-0557) was to 1) Identify by both biochemical and immunohistochemical techniques the abundance and distribution of phospho-Stat3 in primary breast cancer samples. We determined that unless the primary sample was "processed" within 30 minutes of removal from the patient, that the levels of phospho-Stat3 decreased substantially. Analysis of archival paraffin tissue sections gave mixed results regarding the strength of the phospho-Stat3 signal. However, tissue arrays gave the most reproducible results and revealed that ~ 35% of primary breast cancer samples were surples own and head head head and munchistochemical techniques that was between the and Pk but an inverse correlation with her2neu was observed in those samples expressing strong p-Stat3. We examined levels of the Stat3 negative regulator, PLAS3 mRNA in matched normal versus tumour samples and determined (to our surpris							
12. Abstract (Maximum 200 Words) (abstract should contain no proprietary or confidential information) In a growing number of cancers and cancer derived cell lines, where growth factor dysregulation is often at the heart of transformation, Stat3 (one of the STAT proteins) is constitutively activated. In a number of cancer derived cell lines, constitutively activated Stat3 is either required for transformation, enhances transformation or blocks apoptosis. Introduction of either anti-sense or dominant negative Stat3 in a number of cancer derived cell lines including breast cancer leads to their apoptosis. We have engineered a constitutively dimerizeable Stat3, termed Stat3-C, which is capable of inducing cell transformation of immortalized breast epithelial cells, thus qualifying activated Stat3 as a proto-oncogene. The purpose of the Concept Proposal (DAMD17-01-1-0557) was to 1) Identify by both biochemical and immunohistochemical techniques the abundance and distribution of phospho-Stat3 in primary breast cancer samples. We determined that unless the primary sample was "processed" within 30 minutes of removal from the patient, that the levels of phospho-Stat3 signal. However, tissue arrays gave the most reproducible results and revealed that ~ 35% of primary breast cancer samples contained high levels of phospho-Stat3. A positive correlation with ER and PR but an inverse correlation with her2neu was observed in those samples expressing strong P-Stat3. We examined levels of the Stat3 negative regulator, PIAS3 mRNA in matched normal versus tumour samples and determined (to our surprise) that PIAS3 levels were higher in the tumors containing phospho-Stat3. We generated MMTV Stat3-C mice in collaboration with Robert Schriber. Unfortunately, Stat3-C expression is exceedingly low and the animals do not have any unusual phenotype. 14. SUBJECT TERMS 15. NUMBER OF PAGES stats, breast carcinogen	120 DISTRIBUTION / AVAILABILIT	V STATEMENT			12b. DISTRIBUTION CODE		
13. Abstract (Maximum 200 Words) (abstract should contain no proprietary or confidential information) In a growing number of cancers and cancer derived cell lines, where growth factor dysregulation is often at the heart of transformation, Stat3 (one of the STAT proteins) is constitutively activated. In a number of cancer derived cell lines, constitutively activated Stat3 is either required for transformation, enhances transformation or blocks apoptosis. Introduction of either anti-sense or dominant negative Stat3 in a number of cancer derived cell lines including breast cancer leads to their apoptosis. We have engineered a constitutively dimerizeable Stat3, termed Stat3-C, which is capable of inducing cell transformation of immortalized breast epithelial cells, thus qualifying activated Stat3 as a proto-oncogene. The purpose of the Concept Proposal (DAMD17-01-1-0557) was to 1) Identify by both biochemical and immunohistochemical techniques the abundance and distribution of phospho-Stat3 in primary breast cancer samples. We determined that unless the primary sample was "processed" within 30 minutes of removal from the patient, that the levels of phospho-Stat3 signal. However, tissue arrays gave the most reproducible results and revealed that ~ 35% of primary breast cancer samples contained high levels of phospho-Stat3. A positive correlation with HerZneu was observed in those samples and determined (to our surprise) that PIAS3 levels were higher in the tumors containing phospho-Stat3. We generated MMTV Stat3-C mice in collaboration with Robert Schriber. Unfortunately, Stat3-C expression is exceedingly low and the animals do not have any unusual phenotype. 14. SUBJECT TERMS 15. NUMBER OF PAGES stats , breast carcinogenesis, immunohistochemistry, breast cancer 20. LIMITATION OF ABSTRACT 9 16. PRICE CODE <td>Approved for Public Re</td> <td>lease; Distribution Uni</td> <td>limited</td> <td></td> <td></td>	Approved for Public Re	lease; Distribution Uni	limited				
13. Abstract (Maximum 200 Words) (abstract should contain no proprietary or confidential information) In a growing number of cancers and cancer derived cell lines, where growth factor dysregulation is often at the heart of transformation, stat3 (one of the STAT proteins) is constitutively activated. In a number of cancer derived cell lines, constitutively activated Stat3 is either required for transformation, enhances transformation or blocks apoptosis. Introduction of either anti-sense or dominant negative Stat3 in a number of cancer derived cell lines including breast cancer leads to their apoptosis. We have engineered a constitutively dimerizeable Stat3, termed Stat3-C, which is capable of inducing cell transformation of immortalized breast epithelial cells, thus qualifying activated Stat3 as a proto-oncogene. The purpose of the Concept Proposal (DAMD17-01-1-0557) was to 1) Identify by both biochemical and immunohistochemical techniques the abundance and distribution of phospho-Stat3 in primary breast cancer samples. We determined that unless the primary sample was "processed" within 30 minutes of removal from the patient, that the levels of phospho-Stat3 decreased substantially. Analysis of archival paraffin tissue sections gave mixed results regarding the strength of the phospho-Stat3 signal. However, tissue arrays gave the most reproducible results and revealed that ~ 35% of primary breast cancer samples contained high levels of phospho-Stat3. We examined levels of the Stat3 negative regulator, PIAS3 mRNA in matched normal versus tumour samples and determined (to our surprise) that PIAS3 levels were higher in the tumors containing phospho-Stat3. We generated MMTV Stat3-C mice in collaboration with Robert Schriber. Unfortunately, Stat3-C expression is exceedingly low and the animals do not have any unusual phenotype. 14. SUBJECT TERMS 18. SECURITY CLASSIFICATION OF ABSTRACT 19. S							
13. Abstract (Maximum 200 Words) (abstract should contain no proprietary or confidential information) In a growing number of cancers and cancer derived cell lines, where growth factor dysregulation is often at the heart of transformation, Stat3 (one of the STAT proteins) is constitutively activated. In a number of cancer derived cell lines, constitutively activated Stat3 is either required for transformation, enhances transformation or blocks apoptosis. Introduction of either anti-sense or dominant negative Stat3 in a number of cancer derived cell lines including breast cancer leads to their apoptosis. We have engineered a constitutively dimerizeable Stat3, termed Stat3-C, which is capable of inducing cell transformation of immortalized breast epithelial cells, thus qualifying activated Stat3 as a proto-oncogene. The purpose of the Concept Proposal (DAMD17-01-1-0557) was to 1) Identify by both biochemical and immunohistochemical techniques the abundance and distribution of phospho-Stat3 in primary breast cancer samples. We determined that unless the primary sample was "processed" within 30 minutes of removal from the patient, that the levels of phospho-Stat3 decreased substantially. Analysis of archival paraffin tissue sections gave mixed results regarding the strength of the phospho-Stat3 decreased substantially. Analysis of archival paraffin tissue sections gave mixed results regarding the strength of the phospho-Stat3 decreased substantially. Analysis of archival paraffin tissue sections gave mixed results regarding the strength of the phospho-Stat3 were samples and determined (to our surprise) that PIAS3 levels were higher in the tumors containing phospho-Stat3. We generated MMTV Stat3-C mice in collaboration with Robert Schriber. Unfortunately, Stat3-C expression is exceedingly low and the animals do not have any unusual phenotype. 14. SUBJECT TERMS 18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified							
In a growing number of cancers and cancer derived cell lines, where growth factor dysregulation is often at the heart of transformation, Stat3 (one of the STAT proteins) is constitutively activated. In a number of cancer derived cell lines, constitutively activated Stat3 is either required for transformation, enhances transformation or blocks apoptosis. Introduction of either anti-sense or dominant negative Stat3 in a number of cancer derived cell lines including breast cancer leads to their apoptosis. We have engineered a constitutively dimerizeable Stat3, termed Stat3-C, which is capable of inducing cell transformation of immortalized breast epithelial cells, thus qualifying activated Stat3 as a proto-oncogene. The purpose of the Concept Proposal (DAMD17-01-10557) was to 1) Identify by both biochemical and immunohistochemical techniques the abundance and distribution of phospho-Stat3 in primary breast cancer samples. We determined that unless the primary sample was "processed" within 30 minutes of removal from the patient, that the levels of phospho-Stat3 decreased substantially. Analysis of archival paraffin tissue sections gave mixed results regarding the strength of the phospho-Stat3 signal. However, tissue arrays gave the most reproducible results and revealed that ~ 35% of primary breast cancer samples contained high levels of phospho-Stat3. A positive correlation with ER and PR but an inverse correlation with her2neu was observed in those samples and determined (to our surprise) that PIAS3 levels were higher in the tumors containing phospho-Stat3. We generated MMTV Stat3-C mice in collaboration with Robert Schriber. Unfortunately, Stat3-C expression is exceedingly low and the animals do not have any unusual phenotype. 14. SUBJECT TERMS 18. SECURITY CLASSIFICATION OF ABSTRACT 19. SECURITY CLASSIFICATION OF ABSTRACT 20. LIMITATION OF ABSTRACT 9 16.	13. Abstract (Maximum 200 Words)	(abstract should contain no proprietar	v or confidential informatio	on)	I		
transformation, Stat3 (one of the STAT proteins) is constitutively activated. In a number of cancer derived cell lines, constitutively activated Stat3 is either required for transformation, enhances transformation or blocks apoptosis. Introduction of either anti-sense or dominant negative Stat3 in a number of cancer derived cell lines including breast cancer leads to their apoptosis. We have engineered a constitutively dimerizeable Stat3, termed Stat3-C, which is capable of inducing cell transformation of immortalized breast epithelial cells, thus qualifying activated Stat3 as a proto-oncogene. The purpose of the Concept Proposal (DAMD17-01-1-0557) was to 1) Identify by both biochemical and immunohistochemical techniques the abundance and distribution of phospho-Stat3 in primary breast cancer samples. We determined that unless the primary sample was "processed" within 30 minutes of removal from the patient, that the levels of phospho-Stat3 decreased substantially. Analysis of archival paraffin tissue sections gave mixed results regarding the strength of the phospho-Stat3 ignal. However, tissue arrays gave the most reproducible results and revealed that ~ 35% of primary breast cancer samples contained high levels of phospho-Stat3. A positive correlation with ER and PR but an inverse correlation with her2neu was observed in those samples expressing strong p-Stat3. We examined levels of the Stat3 negative regulator, PIAS3 mRNA in matched normal versus tumour samples and determined (to our surprise) that PIAS3 levels were higher in the tumors containing phospho-Stat3. We generated MMTV Stat3-C mice in collaboration with Robert Schriber. Unfortunately, Stat3-C expression is exceedingly low and the animals do not have any unusual phenotype. 14. SUBJECT TERMS 18. SECURITY CLASSIFICATION OF ABSTRACT 19. SECURITY CLASSIFICATION OF ABSTRACT 20. LIMITATION OF ABSTRACT 9 16. PRICE CODE	In a growing number of cancers	and cancer derived cell lines, when	e growth factor dysreg	ulation is often	at the heart of		
activated Stat3 is either required for transformation, enhances transformation or blocks apoptosis. Introduction of either anti-sense or dominant negative Stat3 in a number of cancer derived cell lines including breast cancer leads to their apoptosis. We have engineered a constitutively dimerizeable Stat3, termed Stat3-C, which is capable of inducing cell transformation of immortalized breast epithelial cells, thus qualifying activated Stat3 as a proto-oncogene. The purpose of the Concept Proposal (DAMD17-01-1-0557) was to 1) Identify by both biochemical and immunohistochemical techniques the abundance and distribution of phospho-Stat3 in primary breast cancer samples. We determined that unless the primary sample was "processed" within 30 minutes of removal from the patient, that the levels of phospho-Stat3 decreased substantially. Analysis of archival paraffin tissue sections gave mixed results regarding the strength of the phospho-Stat3 decreased substantially. Analysis of archival paraffin tissue sections gave mixed results regarding the strength of the phospho-Stat3 signal. However, tissue arrays gave the most reproducible results and revealed that ~35% of primary breast cancer samples contained high levels of phospho-Stat3. A positive correlation with Ref and PR but an inverse correlation with her2neu was observed in those samples expressing strong p-Stat3. We examined levels of the Stat3 negative regulator, PIAS3 mRNA in matched normal versus tumour samples and determined (to our surprise) that PIAS3 levels were higher in the tumors containing phospho-Stat3. We generated MMTV Stat3-C mice in collaboration with Robert Schriber. Unfortunately, Stat3-C expression is exceedingly low and the animals do not have any unusual phenotype. 14. SUBJECT TERMS 18. SECURITY CLASSIFICATION OF ABSTRACT 19. SECURITY CLASSIFICATION OF ABSTRACT 9 16. PRICE CODE 20. LIM	transformation, Stat3 (one of the	STAT proteins) is constitutively a	ctivated. In a number of	of cancer derive	d cell lines, constitutively		
On dominant light of the function of the order derived of inducing cells transformation of immortalized engineered a constitutively dimerizeable Stat3, termed Stat3-C, which is capable of inducing cell transformation of immortalized breast epithelial cells, thus qualifying activated Stat3 as a proto-oncogene. The purpose of the Concept Proposal (DAMD17-01-1-0557) was to 1) Identify by both biochemical and immunohistochemical techniques the abundance and distribution of phospho-Stat3 in primary breast cancer samples. We determined that unless the primary sample was "processed" within 30 minutes of removal from the patient, that the levels of phospho-Stat3 decreased substantially. Analysis of archival paraffin tissue sections gave mixed results regarding the strength of the phospho-Stat3 signal. However, tissue arrays gave the most reproducible results and revealed that ~35% of primary breast cancer samples contained high levels of phospho-Stat3. A positive correlation with ER and PR but an inverse correlation with her2neu was observed in those samples and determined (to our surprise) that PIAS3 levels were higher in the tumors containing phospho-Stat3. We generated MMTV Stat3-C mice in collaboration with Robert Schriber. Unfortunately, Stat3-C expression is exceedingly low and the animals do not have any unusual phenotype. 14. SUBJECT TERMS 18. SECURITY CLASSIFICATION OF REPORT 19. SECURITY CLASSIFICATION OF ABSTRACT 20. LIMITATION OF ABSTRACT 17. SECURITY CLASSIFICATION OF THIS PAGE 0F THIS PAGE 19. SECURITY CLASSIFICATION OF ABSTRACT 20. LIMITATION OF ABSTRACT 18. NT 7540-01-280-5500 Standard Form 298 (Rev. 2-89) Prescription to 290. Prescription to 290. Prescription to 290. Prescription to 200. Prescription to 200. Prescription to 200. Prescription to 200. Pres	activated Stat3 is either required or dominant negative Stat3 in a n	for transformation, enhances transformation, enhances transformation, enhances transformation transf	formation or blocks apo	ptosis. Introdu r leads to their a	apoptosis We have		
breast epithelial cells, thus qualifying activated Stat3 as a proto-oncogene. The purpose of the Concept Proposal (DAMD17-01-1-0557) was to 1) Identify by both biochemical and immunohistochemical techniques the abundance and distribution of phospho-Stat3 in primary breast cancer samples. We determined that unless the primary sample was "processed" within 30 minutes of removal from the patient, that the levels of phospho-Stat3 decreased substantially. Analysis of archival paraffin tissue sections gave mixed results regarding the strength of the phospho-Stat3 decreased substantially. Analysis of archival paraffin tissue sections gave mixed results regarding the strength of the phospho-Stat3 decreased substantially. Analysis of archival paraffin tissue sections gave mixed results regarding the strength of the phospho-Stat3 signal. However, tissue arrays gave the most reproducible results and revealed that ~ 35% of primary breast cancer samples contained high levels of phospho-Stat3. A positive correlation with ER and PR but an inverse correlation with her2neu was observed in those samples expressing strong p-Stat3. We examined levels of the Stat3 negative regulator, PIAS3 mRNA in matched normal versus tumour samples and determined (to our surprise) that PIAS3 levels were higher in the tumors containing phospho-Stat3. We generated MMTV Stat3-C mice in collaboration with Robert Schriber. Unfortunately, Stat3-C expression is exceedingly low and the animals do not have any unusual phenotype. 14. SUBJECT TERMS stats, breast carcinogenesis, immunohistochemistry, breast cancer 15. NUMBER OF PAGES 16. PRICE CODE 17. SECURITY CLASSIFICATION OF REPORT Unclassified 18. SECURITY CLASSIFICATION OF REPORT Unclassified NSN 7540-01-280-5500 Standard Form 298 (Rev. 2-89) Terretor by AMS Set 72*41	engineered a constitutively dimen	izeable Stat3, termed Stat3-C, whi	ch is capable of induci	ing cell transfor	mation of immortalized		
0557) was to 1) Identify by both biochemical and immunohistochemical techniques the abundance and distribution of phospho-Stat3 in primary breast cancer samples. We determined that unless the primary sample was "processed" within 30 minutes of removal from the patient, that the levels of phospho-Stat3 decreased substantially. Analysis of archival paraffin tissue sections gave mixed results regarding the strength of the phospho-Stat3 decreased substantially. Analysis of archival paraffin tissue sections gave mixed results regarding the strength of the phospho-Stat3 signal. However, tissue arrays gave the most reproducible results and revealed that ~ 35% of primary breast cancer samples contained high levels of phospho-Stat3. A positive correlation with ER and PR but an inverse correlation with her2neu was observed in those samples expressing strong p-Stat3. We examined levels of the Stat3 negative regulator, PIAS3 mRNA in matched normal versus tumour samples and determined (to our surprise) that PIAS3 levels were higher in the tumors containing phospho-Stat3. We generated MMTV Stat3-C mice in collaboration with Robert Schriber. Unfortunately, Stat3-C expression is exceedingly low and the animals do not have any unusual phenotype. 14. SUBJECT TERMS 15. NUMBER OF PAGES stats , breast carcinogenesis , immunohistochemistry , breast cancer 9 16. PRICE CODE 17. SECURITY CLASSIFICATION OF THIS PAGE Unclassified 19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified 20. LIMITATION OF ABSTRACT Unclassified NSN 7540-01-280-5500 Valuational determined in unclassified 19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified 20. LIMITATION OF ABSTRACT ON PROVINCLASSIFICATION OF ABSTRACT ON PROVINCLASSIFICATION OF ABSTRACT ON PROVINCLASSIFICATION OF	breast epithelial cells, thus qualif	ying activated Stat3 as a proto-onc	ogene. The purpose of	the Concept Pr	coposal (DAMD17-01-1-		
In primary breast cancer samples. We determined that unless the primary sample was "processed" within 30 minutes of removal from the patient, that the levels of phospho-Stat3 decreased substantially. Analysis of archival paraffin tissue sections gave mixed results regarding the strength of the phospho-Stat3 signal. However, tissue arrays gave the most reproducible results and revealed that ~ 35% of primary breast cancer samples contained high levels of phospho-Stat3. A positive correlation with ER and PR but an inverse correlation with her2neu was observed in those samples expressing strong p-Stat3. We examined levels of the Stat3 negative regulator, PIAS3 mRNA in matched normal versus tumour samples and determined (to our surprise) that PIAS3 levels were higher in the tumors containing phospho-Stat3. We generated MMTV Stat3-C mice in collaboration with Robert Schriber. Unfortunately, Stat3-C expression is exceedingly low and the animals do not have any unusual phenotype. 14. SUBJECT TERMS 15. NUMBER OF PAGES 9 16. PRICE CODE 17. SECURITY CLASSIFICATION OF REPORT 18. SECURITY CLASSIFICATION OF THIS PAGE 19. SECURITY CLASSIFICATION OF ABSTRACT 0F REPORT Unclassified Unclassified Unclassified NSN 7540-01-280-5500 Standard Form 298 (Rev. 2-89)	0557) was to 1) Identify by both biochemical and immunohistochemical techniques the abundance and distribution of phospho-Stat3						
How the partent, that the reversion phospho-State decreased abstantially. Finally is of arona participate sections give inked results regarding the strength of the phospho-Stat3 signal. However, tissue arrays gave the most reproducible results and revealed that ~ 35% of primary breast cancer samples contained high levels of phospho-Stat3. A positive correlation with ER and PR but an inverse correlation with her2neu was observed in those samples expressing strong p-Stat3. We examined levels of the Stat3 negative regulator, PIAS3 mRNA in matched normal versus tumour samples and determined (to our surprise) that PIAS3 levels were higher in the tumors containing phospho-Stat3. We generated MMTV Stat3-C mice in collaboration with Robert Schriber. Unfortunately, Stat3-C expression is exceedingly low and the animals do not have any unusual phenotype. 14. SUBJECT TERMS 15. NUMBER OF PAGES stats, breast carcinogenesis, immunohistochemistry, breast cancer 9 16. PRICE CODE 18. SECURITY CLASSIFICATION OF THIS PAGE 19. SECURITY CLASSIFICATION OF ABSTRACT 20. LIMITATION OF ABSTRACT Unclassified Unclassified Unclassified Unclassified Unclassified NSN 7540-01-280-5500 Standard Form 298 (Rev. 2-89) Standard Form 298 (Rev. 2-89)	in primary breast cancer samples. We determined that unless the primary sample was "processed" within 30 minutes of removal						
that ~ 35% of primary breast cancer samples contained high levels of phospho-Stat3. A positive correlation with ER and PR but an inverse correlation with her2neu was observed in those samples expressing strong p-Stat3. We examined levels of the Stat3 negative regulator, PIAS3 mRNA in matched normal versus tumour samples and determined (to our surprise) that PIAS3 levels were higher in the tumors containing phospho-Stat3. We generated MMTV Stat3-C mice in collaboration with Robert Schriber. Unfortunately, Stat3-C expression is exceedingly low and the animals do not have any unusual phenotype. 14. SUBJECT TERMS 15. NUMBER OF PAGES stats, breast carcinogenesis, immunohistochemistry, breast cancer 9 16. PRICE CODE 18. SECURITY CLASSIFICATION OF THIS PAGE 19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified Unclassified Unclassified Unlimited NSN 7540-01-280-5500 Standard Form 298 (Rev. 2-89) Standard Form 298 (Rev. 2-89)	results regarding the strength of the phospho-Stat3 signal However tissue arrays gave the most reproducible results and revealed						
inverse correlation with her2neu was observed in those samples expressing strong p-Stat3. We examined levels of the Stat3 negative regulator, PIAS3 mRNA in matched normal versus tumour samples and determined (to our surprise) that PIAS3 levels were higher in the tumors containing phospho-Stat3. We generated MMTV Stat3-C mice in collaboration with Robert Schriber. Unfortunately, Stat3-C expression is exceedingly low and the animals do not have any unusual phenotype. 14. SUBJECT TERMS stats, breast carcinogenesis, immunohistochemistry, breast cancer 15. NUMBER OF PAGES stats, breast carcinogenesis, immunohistochemistry, breast cancer 17. SECURITY CLASSIFICATION OF REPORT Unclassified 18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified 19. SECURITY CLASSIFICATION OF THIS PAGE Unclassified NSN 7540-01-280-5500 Standard Form 298 (Rev. 2-89) Standard Form 298 (Rev. 2-89)	that ~ 35% of primary breast cancer samples contained high levels of phospho-Stat3. A positive correlation with ER and PR but an						
regulator, PIAS3 mRNA in matched normal versus tumour samples and determined (to our surprise) that PIAS3 levels were higher in the tumors containing phospho-Stat3. We generated MMTV Stat3-C mice in collaboration with Robert Schriber. Unfortunately, Stat3-C expression is exceedingly low and the animals do not have any unusual phenotype. 14. SUBJECT TERMS 14. SUBJECT TERMS 15. NUMBER OF PAGES stats, breast carcinogenesis, immunohistochemistry, breast cancer 9 16. PRICE CODE 16. PRICE CODE 17. SECURITY CLASSIFICATION 18. SECURITY CLASSIFICATION 19. SECURITY CLASSIFICATION OF REPORT Unclassified Unclassified Unclassified NSN 7540-01-280-5500 Standard Form 298 (Rev. 2-89) Preservend by ANSI Std 730-18	inverse correlation with her2neu was observed in those samples expressing strong p-Stat3. We examined levels of the Stat3 negative						
14. SUBJECT TERMS stats, breast carcinogenesis, immunohistochemistry, breast cancer 17. SECURITY CLASSIFICATION OF REPORT 18. SECURITY CLASSIFICATION OF THIS PAGE 0F THIS PAGE Unclassified 18. SECURITY CLASSIFICATION OF ABSTRACT 0F ABSTRACT Unclassified Unclassified <t< td=""><td colspan="6">regulator, PIAS3 mRNA in matched normal versus tumour samples and determined (to our surprise) that PIAS3 levels were higher in the tumore containing rhearbo Stat2. We concreted MMTV Stat2 C miss in collaboration with Babart Schriber. Unfortunately</td></t<>	regulator, PIAS3 mRNA in matched normal versus tumour samples and determined (to our surprise) that PIAS3 levels were higher in the tumore containing rhearbo Stat2. We concreted MMTV Stat2 C miss in collaboration with Babart Schriber. Unfortunately						
14. SUBJECT TERMS stats, breast carcinogenesis, immunohistochemistry, breast cancer 15. NUMBER OF PAGES 9 17. SECURITY CLASSIFICATION OF REPORT Unclassified 18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified 19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified 20. LIMITATION OF ABSTRACT Unclassified NSN 7540-01-280-5500 Standard Form 298 (Rev. 2-89) Dreserthed by ANSI Std 730-18	Stat3-C expression is exceedingly	v low and the animals do not have	any unusual phenotype		Semiller. Onfortunatery,		
14. SUBJECT TERMS stats, breast carcinogenesis, immunohistochemistry, breast cancer 15. NUMBER OF PAGES 9 16. PRICE CODE 17. SECURITY CLASSIFICATION OF REPORT Unclassified 18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified 19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified 20. LIMITATION OF ABSTRACT Unclassified NSN 7540-01-280-5500 Standard Form 298 (Rev. 2-89) Described by ANSI Std 730-18			5 1 51				
stats, breast carcinogenesis, immunohistochemistry, breast cancer 9 17. SECURITY CLASSIFICATION OF REPORT Unclassified 18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified 19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified 20. LIMITATION OF ABSTRACT Unclassified NSN 7540-01-280-5500 Value Standard Form 298 (Rev. 2-89) Drescribed by ANSI Std 739-18	14. SUBJECT TERMS stats, breast carcinogenesis, immunohistochemistry, breast c				15. NUMBER OF PAGES		
17. SECURITY CLASSIFICATION OF REPORT 18. SECURITY CLASSIFICATION OF THIS PAGE 19. SECURITY CLASSIFICATION OF ABSTRACT 20. LIMITATION OF ABSTRACT Unclassified Unclassified Unclassified Unlimited NSN 7540-01-280-5500 Standard Form 298 (Rev. 2-89) Prescribed by ANSI Std 730-18				cancer	9 16 PRICE CODE		
17. SECURITY CLASSIFICATION OF REPORT Unclassified 18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified 19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified 20. LIMITATION OF ABSTRACT Unlimited NSN 7540-01-280-5500 0F ABSTRACT Unclassified 0F ABSTRACT Unclassified Unclassified Unlimited							
Unclassified Unclassified Unclassified Unclassified NSN 7540-01-280-5500 Standard Form 298 (Rev. 2-89)	17. SECURITY CLASSIFICATION	18. SECURITY CLASSIFICATION	19. SECURITY CLASS	FICATION	20. LIMITATION OF ABSTRACT		
NSN 7540-01-280-5500 Standard Form 298 (Rev. 2-89)	Unclassified	Unclassified	Unclassif	ied	Unlimited		
	NSN 7540-01-280-5500			Sta	ndard Form 298 (Rev. 2-89) cribed by ANSI Std. 739-18		

Table of Contents

`

.

Cover1
SF 2982
Table of Contents3
Introduction4
Body5
Key Research Accomplishments8
Reportable Outcomes9
Conclusions9
References9
Appendices

The Role of Stat3 in Breast Cancer Tumorigenesis Jacqueline F. Bromberg

Introduction

Signal Transducers and Activators of Transcription (STATs) are a family of transcription factors which are normally "inactive" within the cytoplasm of cells and upon tyrosine phosphorylation become "activated" which leads to the dimerization of two Stat molecules. Dimerized Stats are translocated into the nucleus where they bind DNA and activate transcription. Stat dimers are dephosphorylated within the nucleus and transported back to the cytoplasm (1). Virtually all growth factor receptors, cytokines, and tyrosine kinases lead to the phosphorylation of one or more Stat proteins. In "normal" cells this activation is transient, while in an ever growing number of primary tumors and cancer derived cell lines Stat proteins (in particular Stat3) are constitutively activated (1, 2). A causal association between activated Stat3 and cellular transformation or oncogenesis has been made in a large number of cancer derived cell lines. Specifically, removal of Stat3 by the introduction of a dominant negative Stat3 molecule or anti-sense molecule leads to a reversal of the transformed phenotype, induction of apoptosis, decreased angiogenesis or growth arrest (Figure 1).

Constitutive Activation of STATs in Primary Cancers and Tumor Derived Cell Lines

Solid Tumors Activated STA		Liquid Tumors	Activated STAT
Breast Cancer	1.3	Chronic Myelogenous Leukemia (CML)	5
Head and Neck	1.3	Acute Myeloid Leukemia (AML)	1,3,5
Cancer	3	Chronic Lymphocytic Leukemia (CLL)	1,3
Prostate Cancer	3	Mycosis Fungoides (MF)	3
Melanoma	3	Acute Lymphoblastic Leukemia (ALL)	1,5
Ovarian Cancer	1.3	Erythroleukemia	1,5
Lung Cancer	1.3	Burkitt's lymphoma	3
Brain Tumors	3	Large granular lymphocyte (LGL)	3
Pancreatic	3	leukemia	3
Danal Carainama		Myeloma	3
		Hodgkins Lymphoma	3
		Anonlactic Large Cell Lymphome	

Cell Lines/Primary Tumor	Required STAT	Oncogenes	Required STAT
Breast Cancer	3	src	3
Head and Neck Cancer	3	eyk	3
Prostate Cancer	3	ret	3
Melanoma	3	lck	3,5
Thyroid Cancer	3	Galphao	3
Myeloma	3	Npm-alk	3
Hodgkins	3	•	
LGL	3		
HCC	3		

Figure 1. Many primary tumors contain constitutively activated Stat3, 5 and 1. Stat3 is required for transformation in the above mentioned tumors as determined by introduction of dominant negative Stat3 molecules and observing growth arrest and or apoptosis.

The Role of Stat3 in Breast Cancer Tumorigenesis Jacqueline F. Bromberg

It has been determined that Stat3 is constitutively activated in primary breast cancer samples, and in a number of breast cancer derived cell lines (Figure 2) (3).



Figure 2. Primary breast cancer samples contain higher levels of Stat3 binding activity in comparison to matched normal tissue.

Furthermore, expression of a dominant negative Stat3 in one of these cell lines (MDA-MB468) promotes its apoptosis(4). In studies performed in rodent fibroblasts, we have demonstrated both the requirement and sufficiency of activated Stat3 in mediating cellular transformation (5, 6, 7). Specifically, we designed a constitutively active mutant form of Stat3 which is dimerized by cysteine-cysteine residues instead of pY-SH2 interactions which can transform immortalized cultured fibroblasts. The use of primary human mammary epithelial (HMEC) cells and immortalized HMEC cell lines are an established *in vitro* model system for studying breast epithelial cell growth and malignant transformation. As it was determined in rodent fibroblasts, we have successfully introduced Stat3-C into 2 different immortalized HMEC derived cell lines (MCF-10A and HMLER). The Stat3-C complemented cells are transformed as determined by anchorage independent growth (our unpublished data).

Given the prevalence of activated Stat3 in primary breast cancer derived cell lines and the sufficiency of activated Stat3 to mediate cellular transformation of rodent fibroblasts, we proposed examining the specific role of constitutively activated Stat3 in breast carcinogenesis, including the prevalence of activated Stat3 in primary breast cancer samples, the abundance and activity of regulators of Stat3 and in transgenic models of breast cancer.

Body

Here we demonstrate that in matched tumor and normal tissue Stat3 is predominantly activated in the tumor samples and not in the normal samples (Figure 2). We went on to develop an immunohistochemical approach to defining the abundance and distribution of activated Stat3 in primary breast cancer samples. We initially observed variable results with archived paraffin sections of breast cancer specimens and suspected that depending on the length of time the primary specimen was left "un-processed" might lead to differences in the phospho-Stat3 signal. In order to address this concern, we obtained fresh samples from the operating room and froze a portion of the sample immediately keeping the remainder on ice for one hour after which time we froze the sample in liquid nitrogen and processed both for analysis of phospho-Stat3 by The Role of Stat3 in Breast Cancer Tumorigenesis Jacqueline F. Bromberg

western blot analysis and immunohistochemistry. Our results demonstrate that the phospho-Stat3 signal is significantly reduced in the samples which were kept on ice for one hour, both by western blot analysis and immunohistochemistry (Figure 3). Interestingly, the intensity of staining for total Stat3 was also reduced. Thus, when analyzing archival sections we first analyzed the total Stat3 signal and if it was reasonably strong we went on to analyze the samples for phospho-Stat3.



Figure 3. Phospho-Stat3 signal is significantly reduced in tumor samples when not processed within one hour from surgery as determined by western blot analysis as well as by immunohistochemistry

We analyzed individual samples (120) and 26 core biopsy samples (tissue arrays) for the abundance and distribution of activated Stat3. Total Stat (both the phosphorylated and unphosphorylated) is highly expressed in normal cells as well as cancerous cells (Figure 4), which is why an antibody specific for the activated or phospho-Stat3 was utilized in determining where activated Stat3 was localized. Essentially, we determined that 35% of the samples stained strongly for pStat3, 30% stained moderately for pStat3 and 35% did not stain at all for pStat3 cells (Figure 5). We then correlated the distribution of activated Stat3 with the expression of known indicators of tumor progression, aggressiveness and differentiation. Tumors that are ER positive are associated with a more favorable prognosis. Despite the lack of a documented molecular link between the estrogen receptor and activated Stat3, determining whether their expression associates with expression of activated Stat3 and ER.



Figure 4. Matched Tumor (on left) and Normal (on right) specimens were stained with anti-phospho Stat3 antibody (top panels) as well as anti-total Stat3 (bottom panel). Normal tissue and cancerous tissue contains abundant total Stat3, while only the Tumor contains high levels of phospho-Stat3.



Figure 5. Immunohistochemistry of primary breast cancer samples. 2 examples/>100 for either strong pStat3, moderate pStat3 or weak pStat3 are shown here.

The Her2/neu receptor is a receptor tyrosine kinase that is over-expressed in a number of breast carcinomas and is suggested to be a poor prognostic indicator of breast cancer development. Our data has shown no statistically significant correlation between activated Stat3 and Her2/neu staining. Interestingly, the majority of the negative pStat3 samples were also negative for Her2/neu and ER. Furthermore, we find strong pStat3 staining in pre-invasive tumors including DCIS, LCIS and invasive tumors.

PSTAT3- 9/26 (35%) ER- 9/26 (35%) Her2/neu- 6/26 (23%)

- \Box 66% of the strong pSTAT3 are also ER+ (p=0.002)
- \Box 11% of the strong pSTAT3 are also Her2/neu+ (p=0.5)

We are in the process of staining these samples for EGFR and PDGFR, both of which can lead to the tyrosine phosphorylation of Stat3. Potential downstream target genes of Stat3 include CyclinD1 and Bcl-xl which are critical targets in the development of murine breast cancer. Bclxl is not overexpressed in our primary breast cancer specimens, at least when compared to positive control lymphoma and myeloma specimens. We are presently determining Cyclin D1 levels. The negative regulators of Stat3 phosphorylation include SHP-2, TcPTP, SOCS1 and PIAS3. By in situ hybridization we determined that PIAS3 levels were increased rather than decreased in all of the breast cancer samples, suggesting that PIAS3 is not differentially regulated nor does it correlate positively or negatively with strong pStat3 samples (data not shown).

In an attempt to examine the functional role of constitutively activated Stat3 in breast tumorigenesis we targeted Stat3-C to murine breast tissue by using an MMTV driven transgene construct expressing Stat3-C. Unfortuntely, these animals never expressed high levels of Stat3-C nor did they reveal any abnormal phenotype. We have good evidence in a variety of different cell lines that low levels of Stat3-C does not lead to constitutive transcriptional activation or cellular transformation. Our approach to overcome this problem is to generate a model of inducible Stat3-C expression in murine breasts. We are in the process of generating this animal.

Key Research Accomplishments

- Phospho-Stat3 is highly expressed in 35% of primary breast cancer specimens.
- Strong pStat3 staining correlates with ER positivity (statistically significant) and inversely with her2neu staining (not statistically significant).
- Phospho-Stat3 staining by immunohistochemistry requires attention to timing in obtaining samples, as this protein is very labile.
- Bcl-xl, a Stat3 target gene is not upregulated in our breast cancer specimens
- PIAS3, a negative regulator of pStat3 activity, is increased in all breast cancer specimens in contrast to normal tissue.
- MMTV-Stat3-C transgenic mice do not express sufficient levels of Stat3-C to permit any conclusive statements to the effects of this protein on proliferation.

The Role of Stat3 in Breast Cancer Tumorigenesis Jacqueline F. Bromberg

Reportable Outcomes

- We are presently preparing a manuscript which will include much of the above mentioned data.
- I presented this work at 2 meetings this year: 1) Keystone Symposia on Jak/Stat Signaling. Utah, 1/2002. 2) National Endocrine Meeting. San Fransisco 6/2002.
- No patents have been submitted or applied for.
- We are applying for funding from the Susan G. Komen Foundation partly based on the data generated from the data presented here.

Conclusions

Constitutive activation of Stat3 is required for transformation of a number of breast carcinoma derived cell lines and more importantly is sufficient for mediating transformation of immortalized breast epithelial cells. Here we demonstrate that persistently activated Stat3 (pStat3) is highly expressed in ~35% of primary breast cancer specimens as well as pre-invasive DCIS and LCIS. Strong pStat3 levels correlate positively with ER staining and negatively with her2neu. One of the important negative regulators of pStat3, PIAS3 is not transcriptionally down regulated in these specimens.

References

- 1. J. Bromberg, J Clin Invest 109, 1139-42. (2002).
- 2. D. E. Levy, J. E. Darnell, Nat Rev Mol Cell Biol 3, 651-62. (2002).
- 3. R. Garcia, et al., Cell Growth Differ 8, 1267-76 (1997).
- 4. R. Garcia, et al., *Oncogene* **20**, 2499-513. (2001).
- 5. J. F. Bromberg, C. M. Horvath, D. Besser, W. W. Lathem, J. E. Darnell, Jr., *Mol. Cell. Biol.* 5, 2553-8 (1998).
- 6. J. Bromberg, et al., *Cell* **98**, 295-303 (1999).
- 7. J. Turkson, et al., Mol Cell Biol 18, 2545-52 (1998).